b) ligand peptides of integrins containing the sequence RGD, fibronectin ligand;

c) chemiotactic factors, formyl-peptides and their antagonists:

FMLP, (N-formyl-Met-Leu-Phe);

d) peptide hormones, α-MSH. ActSYSMEHFRWGKPV-NH₂ (SEQ ID NO: 6) and their antagonists;

C) natural metabolites selected from the group consisting of -biotin.

-carnitine

-tetrahydrofolate and folic acid, which can be both a recognition signal with respect to certain cells having suitable receptors and a destabilizer of cell membranes.

REMARKS

Applicants submit herewith a paper copy of a sequence listing (Exhibit 1), a computer diskette containing the sequence listing (Exhibit 2), and a statement pursuant to 37 CFR §1.825(f) stating that the computer diskette copy of the sequence listing is identical to the paper copy (Exhibit 3).

As required by 37 C.F.R. 1.121, "marked up" versions of the replacement paragraphs of the specification and of the amended claims are attached as Exhibits 4 and 5, respectively with additions indicated by underlining and deletions by brackets.

· Serial No. 09/297,519

Case No. <u>410.015</u>

As the amendments to the specification and claims were simply made to indicate the appropriate SEQ ID NOs in the enclosed sequence listing, no new matter is introduced by this amendment.

Respectfully submitted,
BIERMAN, MUSERLIAN AND LUCAS, L.L.P.

Date: <u>5-1-01</u>

Charles A. Muserlian

Reg. No. 19,683

BIERMAN, MUSERLIAN AND LUCAS, L.L.P. 600 Third Avenue New York, NY 10016 (212) 661-8000 (212) 661-8002 Telecopier